This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

In 1,200 adults with solid tumors, investigators compared measured glomerular filtration rate (mGFR), which directly measures kidney filtration rate using a specialized clearance marker, with commonly used estimated GFR (eGFR) values based on the blood proteins cystatin C and creatinine.

CKD prevalence rates based on mGFR, eGFR based on creatinine and eGFR based on both creatinine and cystatin C were 18.9%, 10.2% and 15.7%, respectively. Among those with mGFR of 45–59 ml/min/1.73 m² (indicating mild to moderate CKD), 72.1% had creatinine-based eGFR >60, suggesting that they had normal kidney function. Among those with mGFR <45 (indicating more advanced CKD), 52.5% had creatinine-based eGFR >45. Adding cystatin C to creatinine improved GFR discrepancy, but concordance remained poor.

These thresholds are especially important for decisions about drug eligibility and dose adjustments, as drug clearance rates often drop as kidney function declines. "The results suggest that errors in GFR estimation may contribute to excessive toxicity in patients with cancer receiving anticancer therapy," said corresponding author Veronica Torres Costa e Silva, M.D., Ph.D., of the University of São Paulo Medical School, in Brazil.

"I'll give the example of cisplatin. 73 m² should not be considered eligible.

Source link